View Older Stories View More Recent Stories
-
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Sha
-
Scilex Holding (SCLX) Issues Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company
-
Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company
-
Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company
-
Sorrento Therapeutics (SRNEQ) Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding
-
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Co
-
Oramed Pharma (ORMP) Announces $101.88M Short-Term Senior Secured Note Transaction with Scilex Holding Company
-
Scilex Holding (SCLX) Enters Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento
-
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Dec
-
Sorrento Therapeutics (SRNEQ) Reports Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients
-
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone T
-
Sorrento Therapeutics (SRNEQ) Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin
-
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
-
Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid
-
Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders
-
Sorrento Announces Launch of Voluntary Offering to Dividend Short Holders with Deadline to Participate by July 27, 2023
-
/C O R R E C T I O N -- Sorrento Therapeutics, Inc./
-
Sorrento Therapeutics' (SRNEQ) Bankruptcy Court Approves Elective Offering of Restricted Common Stock of Scilex Holding Company for Dividend Short Holders
-
Sorrento Therapeutics, Inc.'s Bankruptcy Court Approves Elective Offering of Restricted Common Stock of Scilex Holding Company for Dividend Short Holders
-
Sorrento Therapeutics (SRNEQ) Announces Positive Phase IIa Study Results of Abivertinib
-
Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study
-
Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19
-
Scilex (SCLX) Announces that Sorrento Therapeutics' Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock
-
Scilex Holding Company Announces that Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock
-
Sorrento Therapeutics, Inc.'s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock
-
Sorrento Therapeutics (SRNEQ) Announces $4.6M US Government Contract From the NIAID
-
Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness
-
Sorrento's (SRNEQ) Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms t
-
Sorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Broker
-
Sorrento Therapeutics' (SRNEQ) Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend
-
Scilex Holding (SCLX) Announces Sorrento Therapeutics' Bankruptcy Court Extended the Lockup Period on Shares of Scilex Stock Distributed by Sorrento as Dividend
-
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Notice that Sorrento’s Bankruptcy Court has Extended the Lockup Period on Shares of Scilex S
-
Sorrento Therapeutics, Inc.'s Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend
-
Scilex Holding Company Announces Final Postponement of Annual Meeting of Stockholders
-
Scilex Holding Company Announces Postponement of Annual Meeting of Stockholders
-
Sorrento's (SRNEQ) Bankruptcy Court Requires Brokerages to Provide Information Related to Scilex Common Stock
-
Sorrento Therapeutics, Inc.'s Bankruptcy Court Requires Brokerages to Provide Information Related to Scilex Common Stock
-
Sorrento Therapeutics, Inc. Receives Final Court Approval for $75 Million Debtor-In-Possession Financing
-
Court Confirms Sorrento Therapeutics, Inc.'s $125 Million Arbitration Award Against NantPharma, LLC
